Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outp

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation,

CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration reven

Evercore ISI Group analyst Jonathan Miller upgrades Intellia Therapeutics (NASDAQ:NTLA) from In-L

Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.80) per share which missed the

CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le

Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) have received an average reco

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le

Amova Asset Management Americas Inc. cut its position in shares of Intellia Therapeutics, Inc. (NASD

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid a

Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pha

Wolfe Research analyst Andy Chen downgrades Intellia Therapeutics (NASDAQ:NTLA) from Peer Perform

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral a

Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progr

Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destr

CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le

It might pull it off, provided several things fall right in place.

Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpar

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names whe

Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipel

Stocks are mixed, with the Dow Jones Industrial Average (DJI) trading at fresh record highs once aga

U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% a

There could be additional catalysts for this drugmaker over the next year.

Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by

Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outp

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral

Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA)

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European A

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolution

Intellia will also have a poster presentation detailing the burdens experienced by HAE patients livi

Bernstein analyst William Pickering maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market P

Top Wall Street analysts updated their ratings on top companies. For full list of changes, including

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Intellia Therapeutics (NASDAQ:NTLA)

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy a

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the an

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the an

Cathie Wood trims chip exposure and adds AI platform and biotech bets, offering ETF investors insigh

U.S. stock futures up, Nasdaq 100 gains 100 points. Robinhood shares fall 10.7% after reporting lowe

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy a

Goldman Sachs analyst Salveen Richter maintains Intellia Therapeutics (NASDAQ:NTLA) with a Sell a

Citizens analyst Silvan Turkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outpe

Morgan Stanley analyst Terence Flynn maintains Intellia Therapeutics (NASDAQ:NTLA) with a Equal-W